ArticlePharmaceutics2022

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts.

Annett Klinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.